Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug discovery for Alzheimer's disease: the end of the beginning.

Literature DB >> 15314243

Drug discovery for Alzheimer's disease: the end of the beginning.

Lorenzo M Refolo¹, Howard M Fillit.

Abstract

Entities: Disease

Mesh：

Substances：
Neuroprotective Agents

Year: 2004 PMID： 15314243 DOI： 10.1385/JMN:24:1:001

Source DB: PubMed Journal: J Mol Neurosci ISSN： 0895-8696 Impact factor: 3.444

× No keyword cloud information.

51 in total

1. JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo.

Authors: A Petit; A Pasini; C Alves Da Costa; E Ayral; J F Hernandez; C Dumanchin-Njock; C J Phiel; P Marambaud; S Wilk; M Farzan; P Fulcrand; J Martinez; D Andrau; F Checler
Journal: J Neurosci Res Date: 2003-11-01 Impact factor: 4.164

2. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse.

Authors: E Planel; K Yasutake; S C Fujita; K Ishiguro
Journal: J Biol Chem Date: 2001-07-05 Impact factor: 5.157

Review 3. Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease.

Authors: David M Holtzman; Kelly R Bales; Steven M Paul; Ronald B DeMattos
Journal: Adv Drug Deliv Rev Date: 2002-12-07 Impact factor: 15.470

4. Statins and the risk of dementia.

Authors: H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal: Lancet Date: 2000-11-11 Impact factor: 79.321

Review 5. Alzheimer's disease: the pharmacological pathway.

Authors: Hervé Allain; Danièle Bentué-Ferrer; Olivier Tribut; Serge Gauthier; Bernard-François Michel; Christophe Drieu-La Rochelle
Journal: Fundam Clin Pharmacol Date: 2003-08 Impact factor: 2.748

6. Biochemical and structural characterization of the interaction of memapsin 2 (beta-secretase) cytosolic domain with the VHS domain of GGA proteins.

Authors: Xiangyuan He; Guangyu Zhu; Gerald Koelsch; Karla K Rodgers; Xuejun C Zhang; Jordan Tang
Journal: Biochemistry Date: 2003-10-28 Impact factor: 3.162

3. Biological Evaluation, Molecular Docking, and SAR Studies of Novel 2-(2,4-Dihydroxyphenyl)-1H- Benzimidazole Analogues.

Authors: Joanna Matysiak; Alicja Skrzypek; Monika Karpińska; Kamila Czarnecka; Paweł Szymański; Marek Bajda; Andrzej Niewiadomy
Journal: Biomolecules Date: 2019-12-12

3 in total

Drug discovery for Alzheimer's disease: the end of the beginning.

1. JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo.

2. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse.

Review 3. Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease.

4. Statins and the risk of dementia.

Review 5. Alzheimer's disease: the pharmacological pathway.

6. Biochemical and structural characterization of the interaction of memapsin 2 (beta-secretase) cytosolic domain with the VHS domain of GGA proteins.

7. Characterization of radioiodinated ligand binding to amyloid beta plaques.

Review 8. Role of cdk5 in the pathogenesis of Alzheimer's disease.

Review 9. Discovery of compounds that will prevent tau pathology.

10. Continuing strategies for inhibiting Alzheimer's gamma-secretase.

1. The Future for Dementia Research: a Perspective from the Journal of Molecular Neuroscience.

2. Nanoscience enables ultrasensitive detection of Alzheimer's biomarker.

3. Biological Evaluation, Molecular Docking, and SAR Studies of Novel 2-(2,4-Dihydroxyphenyl)-1H- Benzimidazole Analogues.